CD274 and hepatocellular carcinoma: In the CHECKMATE 040 study, baseline PD-L1 status in tumor cells showed no apparent effect on ORR in patients with advanced HCC treated with nivolumab (TPS≥1% 26% vs TPS<1% 19%) (40).